CREO vs. EKF, IUG, NCYT, POLX, IHC, AVO, MHC, RUA, SUN, and BELL
Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), MyHealthChecked (MHC), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), and Belluscura (BELL). These companies are all part of the "medical devices" industry.
Creo Medical Group vs.
Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
EKF Diagnostics received 221 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.
In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.00 beat EKF Diagnostics' score of -1.04 indicating that Creo Medical Group is being referred to more favorably in the media.
Creo Medical Group has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
EKF Diagnostics has a net margin of 9.37% compared to Creo Medical Group's net margin of -73.93%. EKF Diagnostics' return on equity of 7.03% beat Creo Medical Group's return on equity.
56.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 70.3% of EKF Diagnostics shares are owned by institutional investors. 22.4% of Creo Medical Group shares are owned by company insiders. Comparatively, 5.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
EKF Diagnostics beats Creo Medical Group on 12 of the 15 factors compared between the two stocks.
Get Creo Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creo Medical Group Competitors List
Related Companies and Tools
This page (LON:CREO) was last updated on 3/4/2025 by MarketBeat.com Staff
